Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

Even the coroner specified that the self-inflicted death was an “adverse effect” of the antidepressant the man had been ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Research shows that caffeine inhibits the action of some antibiotics, such as Avelox (moxifloxacin), Noroxin (norfloxacin), ...

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Antidepressants known as selective serotonin reuptake inhibitors, or SSRIs have been the first line of treatment for mood ...

China's National Health Commission plans to address gaps in mental health services from 2025-2027, focusing on youth. Eli ...